Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
MK5 Proteome Network Type I Analysis

Type 1 network in which we propagated the absolute log regulation ratio abs(log(r/g)). We used the filtered lowest boundary of the confidence interval for the microarray measurement based and used the high confidence interaction map. Because type-I networks tend to favour highly connected proteins we tested a normalisation scheme in which we would run the network once with real values (the measured column) and once with simulated values where each measured point is set to 1 instead of the actual signal (the expected column). Afterwards we divided the measured value by the expected value. This normalisation scheme works to a certain extend but will lead to a variance that is directly related to the connectivity of each protein. In the end we dropped the use of Type-I networks due to the many technical problems they pose.
Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Rank Gene description measured expected final Hugo
Results: HTML CSV LaTeX
Showing element 1802 to 1851 of 3206 in total

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
measured\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
expected\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
final\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1802\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RAN BINDING PROTEIN 11. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0547985\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.233549\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234633846\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
IPO11\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1803\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HEPATOCYTE GROWTH FACTOR-REGULATED TYROSINE KINASE SUBSTRATE; HUMAN GROWTH FACTOR-REGULATED TYROSINE KINASE SUBSTRATE. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.24593\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.0482\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234621255\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HGS\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1804\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CONSERVED OLIGOMERIC GOLGI COMPLEX COMPONENT 7. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0361228\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.153963\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234620006\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
COG7\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1805\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GTP CYCLOHYDROLASE I (EC 3.5.4.16) (GTP-CH-I). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.250702\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.06873\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234579361\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GCH1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1806\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
P53-RELATED PROTEIN KINASE (EC 2.7.1.-) (NORI-2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.131908\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.562339\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.23457025\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TP53RK\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1807\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"EARLY ENDOSOME ANTIGEN 1, 162KD; EARLY ENDOSOME-ASSOCIATED PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0387072\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.165025\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234553552\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
EEA1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1808\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.146293\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.623804\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234517573\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
MED9\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1809\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CARBOXYPEPTIDASE A5. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0167711\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0715398\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234430345\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CPA5\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1810\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CARBOXYPEPTIDASE A1 PRECURSOR (EC 3.4.17.1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0213901\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0912429\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234430295\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CPA1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1811\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
AMINOACYLASE-1 (EC 3.5.1.14) (N-ACYL-L-AMINO-ACID AMIDOHYDROLASE) (ACY-1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.18122\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.773023\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234430282\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ACY1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1812\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"NEUTRAL AND BASIC AMINO ACID TRANSPORT PROTEIN RBAT (B(0,+)-TYPE AMINO ACID TRANSPORT PROTEIN) (NBAT) (D2H). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0214423\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0914656\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234430212\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SLC3A1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1813\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CARBOXYPEPTIDASE B PRECURSOR (EC 3.4.17.2) (PANCREAS-SPECIFIC PROTEIN) (PASP). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0139875\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.059666\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234429994\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CPB1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1814\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
60S RIBOSOMAL PROTEIN L9. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.788679\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.36493\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234381993\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1815\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROTEASOME SUBUNIT ALPHA TYPE 7-LIKE (EC 3.4.25.1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.726532\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.09996\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234368185\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PSMA8\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1816\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
UNC-119 PROTEIN HOMOLOG (RETINAL PROTEIN 4) (HRG4). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.183433\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.783008\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234267083\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
UNC119\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1817\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DNA FRAGMENTATION FACTOR ALPHA SUBUNIT (DNA FRAGMENTATION FACTOR 45 KDA SUBUNIT) (DFF-45) (INHIBITOR OF CAD) (ICAD). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0764303\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.326253\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234266965\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DFFA\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1818\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ANKYRIN 3 (ANK-3) (ANKYRIN G). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0299967\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.128045\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234266859\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ANK3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1819\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ADAMTS-9 PRECURSOR (EC 3.4.24.-) (A DISINTEGRIN AND METALLOPROTEINASE WITH THROMBOSPONDIN MOTIFS 9) (ADAM-TS 9) (ADAM-TS9). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0765741\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.326867\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234266842\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ADAMTS9\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1820\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
26S PROTEASOME NON-ATPASE REGULATORY SUBUNIT 8 (26S PROTEASOME REGULATORY SUBUNIT S14) (P31). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.824134\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.51793\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234266742\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PSMD8\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1821\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DNA FRAGMENTATION FACTOR 40 KDA SUBUNIT (EC 3.-.-.-) (DFF-40) (CASPASE-ACTIVATED DEOXYRIBONUCLEASE) (CASPASE-ACTIVATED DNASE) (CAD) (CASPASE-ACTIVATED NUCLEASE) (CPAN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.153292\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.654349\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234266424\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DFFB\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1822\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ADP-RIBOSYLATION FACTOR-LIKE PROTEIN 3. \vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.038359\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.163741\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.234266311\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
ARL3\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1823\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1824\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"ANKYRIN 2 (BRAIN ANKYRIN) (ANKYRIN B) (ANKYRIN, NONERYTHROID). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
ANK2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1825\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.341137\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.45621\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234263602\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RFK\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1826\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROTEASOME SUBUNIT ALPHA TYPE 7 (EC 3.4.25.1) (PROTEASOME SUBUNIT RC6-1) (PROTEASOME SUBUNIT XAPC7). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.813157\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.47138\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234246035\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PSMA7\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1827\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"SERINE/THREONINE PROTEIN PHOSPHATASE 2A, CATALYTIC SUBUNIT, ALPHA ISOFORM (EC 3.1.3.16) (PP2A-ALPHA) (REPLICATION PROTEIN C) (RP-C). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.517007\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.20733\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234222794\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PPP2CA\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1828\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
S-ADENOSYLMETHIONINE SYNTHETASE ALPHA AND BETA FORMS (EC 2.5.1.6) (METHIONINE ADENOSYLTRANSFERASE) (ADOMET SYNTHETASE) (MAT-I/III). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.53545\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.28647\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234181949\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
MAT1A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1829\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
APOPAIN PRECURSOR (EC 3.4.22.-) (CYSTEINE PROTEASE CPP32) (YAMA PROTEIN) (CPP-32) (CASPASE-3) (CASP-3) (SREBP CLEAVAGE ACTIVITY 1) (SCA-1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0223509\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0954818\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234085449\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CASP3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1830\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CASPASE-7 PRECURSOR (EC 3.4.22.-) (ICE-LIKE APOPTOTIC PROTEASE 3) (ICE-LAP3) (APOPTOTIC PROTEASE MCH-3) (CMH-1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.028203\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.120482\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.23408476\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CASP7\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1831\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.263169\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.12425\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234084056\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TSR1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1832\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
VALYL-TRNA SYNTHETASE 2 (EC 6.1.1.9) (VALINE--TRNA LIGASE 2) (VALRS 2) (G7A). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0546688\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.233559\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.234068479\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
VARS\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1833\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
N-ACETYLTRANSFERASE 5 (EC 2.3.1.-). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.101148\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.43244\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.233900657\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
NAT5\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1834\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RIBOSOMAL PROTEIN L24-LIKE; 60S RIBOSOMAL PROTEIN L30 ISOLOG; MY024 PROTEIN; HOMOLOG OF YEAST RIBOSOMAL LIKE PROTEIN 24. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.193647\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.827963\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.23388364\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
C15orf15\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1835\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DNA-DIRECTED RNA POLYMERASE II 7.6 KDA POLYPEPTIDE (EC 2.7.7.6) (RPB10) (RPB7.6) (RPABC5). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.508074\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.17246\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.233870359\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
POLR2L\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1836\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
U6 SNRNA-ASSOCIATED SM-LIKE PROTEIN LSM1 (SMALL NUCLEAR RIBONUCLEAR CASM) (CANCER-ASSOCIATED SM-LIKE). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.31086\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.32969\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.233783814\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
LSM1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1837\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0766245\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.327833\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.233730283\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
C8orf53\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1838\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
0.0910964\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.38998\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.233592492\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
MTHFD1L\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1839\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
40S RIBOSOMAL PROTEIN S24 (S19). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.182207\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.780167\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.233548715\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RPS24\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1840\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0267948\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.114733\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.233540481\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
C18orf22\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1841\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
60S RIBOSOMAL PROTEIN L39. \vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.187564\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.803133\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.233540397\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1842\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
60S RIBOSOMAL PROTEIN L31. \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
RPL31\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1843\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
40S RIBOSOMAL PROTEIN S19. \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
RPS19\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1844\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
60S RIBOSOMAL PROTEIN L18A. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.214359\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.917867\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.233540371\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1845\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MITOCHONDRIAL RIBOSOMAL PROTEIN L22. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0252117\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.107989\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.233465446\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
MRPL22\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1846\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MCT-1 PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0754524\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.323185\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.233465043\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
MCTS1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1847\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"SERYL-TRNA SYNTHETASE, MITOCHONDRIAL PRECURSOR (EC 6.1.1.11) (SERINE--TRNA LIGASE) (SERRSMT). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.215775\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.924279\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.233452237\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SARS2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1848\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SERYL-TRNA SYNTHETASE (EC 6.1.1.11) (SERINE--TRNA LIGASE) (SERRS). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.293395\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.25677\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.233451626\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SARS\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1849\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BA304I5.1 (NOVEL LIPASE) (FRAGMENT). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0224671\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0962388\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.233451581\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
LIPM\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1850\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"TRIACYLGLYCEROL LIPASE, GASTRIC PRECURSOR (EC 3.1.1.3) (GASTRIC LIPASE) (GL). \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.0275767\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.118126\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.233451569\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
LIPF\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1851\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
LYSOSOMAL ACID LIPASE/CHOLESTERYL ESTER HYDROLASE PRECURSOR (EC 3.1.1.13) (LAL) (ACID CHOLESTERYL ESTER HYDROLASE) (STEROL ESTERASE) (LIPASE A) (CHOLESTERYL ESTERASE). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
LIPA\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the bloody hugo identifier as demanded by the BMC Bioinformatics idiots
- http://analysis.yellowcouch.org/